The anti-PD-L1 agent atezolizumab, in combination with various chemotherapy regimens, has been FDA-approved for triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), and non-squamous NSCLC [287,288,289]. The gene discussed is CD274; the disease is small cell lung carcinoma.